Wugen Secures $115M to Advance Allogeneic CAR-T Therapy for T Cell Malignancies

ST. LOUIS, Missouri – Wugen, a clinical-stage biotechnology company, announced today the first close of a $115 million Series C funding round, led by existing investor Fidelity Management & Research Company. The financing will be used to advance the company’s lead program, WU-CART-007, an allogeneic (off-the-shelf) CAR-T cell therapy for T cell malignancies.

The funding provides a significant boost to Wugen as it navigates a shifting market and forges ahead with its allogeneic approach. Unlike autologous cell therapies, which are personalized and costly, Wugen’s off-the-shelf therapy is being developed to offer a more accessible treatment option. The company recently entered a pivotal clinical trial for WU-CART-007 and, if successful, anticipates filing for regulatory approval in 2027.

The Series C funding follows Wugen’s decision last fall to pause development of its natural killer (NK) cell therapy program, WU-NK-101, due to a decline in investor interest in that niche of the cell therapy landscape.

Wugen CEO Kumar Srinivasan stated that the new funding validates the promise of their allogeneic CAR-T platform. The company expects to use the capital to complete its pivotal study and engage in regulatory discussions with the FDA and European Medicines Agency.